JOINT CLINICAL RESEARCH AGREEMENTJoint Clinical Research Agreement • February 25th, 2020 • Exelixis, Inc. • Services-commercial physical & biological research • California
This JOINT CLINICAL RESEARCH AGREEMENT (the “Agreement”) is made and entered into effective as December 18, 2019 (the “Effective Date”) by and between Exelixis, Inc., a Delaware corporation having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502 (“Exelixis”) and F. Hoffmann-La Roche Ltd, a Swiss corporation having an address at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”). Exelixis and Roche may be referred to herein individually as a “Party,” or collectively as the “Parties”.
SUPPLEMENT TO THE JOINT CLINICAL RESEARCH AGREEMENTJoint Clinical Research Agreement • February 25th, 2020 • Exelixis, Inc. • Services-commercial physical & biological research • California
This SUPPLEMENT TO THE JOINT CLINICAL RESEARCH AGREEMENT (the “Supplement”) is made and entered into effective as of December 18, 2019 (the “Effective Date”) by and among Exelixis, Inc. a Delaware corporation, located at 1851 Harbor Bay Parkway, Alameda, CA 94501, (“Exelixis”), F. Hoffmann-La Roche Ltd, a Swiss corporation having an address at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”), and Ipsen Pharma SAS, a French Corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (“Ipsen”). The terms in this Supplement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement.
